Growth hormone secretagogues
CJC-1295.
Written by the Elevate Clinical Team
Medically reviewed by Dr. Eric W. Anderson, MD · Last reviewed
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on .
Also known as with or without DAC
A GHRH analog with extended half-life, studied to raise baseline growth-hormone and IGF-1 signaling.
What it is
CJC-1295 is a modified GHRH analog. The DAC (drug affinity complex) version binds albumin and lasts for days, raising baseline GH; the version without DAC — often called modified GRF (1-29) — acts in a short pulse closer to natural physiology.
What it's studied for
- Sustained IGF-1 elevation in early human trials
- Combined effect with ghrelin-receptor agonists like Ipamorelin
- Body composition and recovery signaling
How it's used in practice
- DAC and non-DAC behave very differently; they are not interchangeable
- IGF-1 monitoring is how response and overshoot are tracked
What you should know before asking about it
- Availability varies and formulations change; not all versions are pharmacy-available
- Contraindicated with active malignancy
- Water retention, joint discomfort and carpal-tunnel-type symptoms are dose-related signals to reduce
Frequently asked questions.
- What is CJC-1295?
- CJC-1295 is a modified GHRH analog. The DAC (drug affinity complex) version binds albumin and lasts for days, raising baseline GH; the version without DAC — often called modified GRF (1-29) — acts in a short pulse closer to natural physiology.
- What is CJC-1295 studied for?
- Published and ongoing research looks at sustained IGF-1 elevation in early human trials; combined effect with ghrelin-receptor agonists like Ipamorelin; body composition and recovery signaling. These are areas of study, not promised outcomes.
- Is CJC-1295 FDA-approved?
- CJC-1295 is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.
- How is CJC-1295 typically used?
- DAC and non-DAC behave very differently; they are not interchangeable. IGF-1 monitoring is how response and overshoot are tracked. Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with CJC-1295?
- Availability varies and formulations change; not all versions are pharmacy-available. Contraindicated with active malignancy. Water retention, joint discomfort and carpal-tunnel-type symptoms are dose-related signals to reduce.
Sources
- 1.Published literature on CJC-1295 with or without DAC— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Medically reviewed by Dr. Eric W. Anderson, MD · Last reviewed . Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Growth hormone secretagogues
Sermorelin
A growth-hormone-releasing hormone analog that prompts your own pituitary output rather than replacing it.
Ipamorelin
A selective growth-hormone secretagogue studied for GH release without meaningful cortisol or prolactin rise.
Tesamorelin
An FDA-approved GHRH analog with the strongest clinical evidence of any peptide for reducing visceral adipose tissue.